Literature DB >> 1698713

Effect of FK506 and cyclosporine on primary and secondary skin allograft survival in mice.

Z Lagodzinski1, A Górski, M Wasik.   

Abstract

The ability of FK506 and cyclosporine to prolong mouse skin allograft survival when given alone and in combination was studied during primary and secondary responses. The drugs were efficient immunosuppressants of both types of anti-graft responses but--as reported earlier--much lower FK506 doses were required to produce those effects. Both agents synergized when administered together during primary responses but not secondary responses. This suggests that the combination treatment may be less successful in a presensitized host, a finding with potential clinical application.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698713      PMCID: PMC1384237     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  6 in total

1.  Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine.

Authors:  N Murase; S Todo; P H Lee; H S Lai; F Chapman; M A Nalesnik; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

2.  Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids.

Authors:  S Todo; A J Demetris; Y Ueda; O Imventarza; K Okuda; A Casavilla; S Cemaj; A Ghalab; V Mazzaferro; B S Rhoe
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

3.  Studies on FK506 in experimental organ transplantation.

Authors:  T Ochiai; K Sakamoto; M Nagata; K Nakajima; T Goto; S Hori; T Kenmochi; T Nakagori; T Asano; K Isono
Journal:  Transplant Proc       Date:  1988-02       Impact factor: 1.066

4.  The effect of FK-506 on hyperacute rejection in presensitized rats.

Authors:  L Makowka; F Chapman; S Qian; A Zerbe; P H Lee; N Murase; R Saunders; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

5.  Prolongation of canine renal allograft survival by treatment with FK-506.

Authors:  T Ochiai; M Nagata; K Nakajima; K Sakamoto; T Asano; K Isono
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

6.  FK 506 for liver, kidney, and pancreas transplantation.

Authors:  T E Starzl; S Todo; J Fung; A J Demetris; R Venkataramman; A Jain
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

  6 in total
  4 in total

1.  Preventing Allograft Rejection by Targeting Immune Metabolism.

Authors:  Chen-Fang Lee; Ying-Chun Lo; Chih-Hsien Cheng; Georg J Furtmüller; Byoungchol Oh; Vinicius Andrade-Oliveira; Ajit G Thomas; Caitlyn E Bowman; Barbara S Slusher; Michael J Wolfgang; Gerald Brandacher; Jonathan D Powell
Journal:  Cell Rep       Date:  2015-10-17       Impact factor: 9.423

Review 2.  Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Authors:  Rita Diehl; Fabienne Ferrara; Claudia Müller; Antje Y Dreyer; Damian D McLeod; Stephan Fricke; Johannes Boltze
Journal:  Cell Mol Immunol       Date:  2016-10-10       Impact factor: 11.530

3.  March1-dependent modulation of donor MHC II on CD103+ dendritic cells mitigates alloimmunity.

Authors:  Thiago J Borges; Naoka Murakami; Felipe D Machado; Ayesha Murshid; Benjamin J Lang; Rafael L Lopes; Laura M Bellan; Mayuko Uehara; Krist H Antunes; Maria José Pérez-Saéz; Gabriel Birrane; Priscila Vianna; João Ismael B Gonçalves; Rafael F Zanin; Jamil Azzi; Reza Abdi; Satoshi Ishido; Jeoung-Sook Shin; Ana Paula D Souza; Stuart K Calderwood; Leonardo V Riella; Cristina Bonorino
Journal:  Nat Commun       Date:  2018-08-28       Impact factor: 14.919

4.  A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection In Vivo.

Authors:  Senthil Jayarajan; Joseph J Meissler; Martin W Adler; Toby K Eisenstein
Journal:  Front Pharmacol       Date:  2022-02-03       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.